Mass General Brigham
Health Plan

Dry Eye Disease:
Miebo (perfluorohexyloctane ophthalmic solution)
Restasis (cyclosporine ophthalmic emulsion)
Restasis Multidose
Tryptyr (acoltrmeon ophthalmic solution)
Xiidra (liftegrast ophthalmic solution)
Effective 01/01/2027

Plan	☐ MassHealth UPPL ☒Commercial/Exchange	**Program Type**	☒ Prior Authorization ☐ Quantity Limit ☐ Step Therapy
Benefit	☒ Pharmacy Benefit ☐ Medical Benefit		
Specialty Limitations	N/A		
Contact Information	**Medical Benefit** **Pharmacy Benefit**	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	N/A		

Overview
Miebo (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for treatment of the signs and symptoms of dry eye disease.

Restasis (cyclosporine ophthalmic emulsion) is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Tryptyr (acoltremon ophthalmic solution) is a TRPM8 thermoreceptor agonist indicated for the treatment of the signs and symptoms of dry eye disease.

Xiidra (lifitegrast ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

Coverage Guidelines
If member is new to the plan (as evidenced by coverage effective date of less than or equal to 90 days), submission of medical records documenting that the member is currently receiving treatment with the requested drug, excluding when the product is obtained as samples or via manufacturer's patient assistance programs
OR
Authorization will be granted when all the following criteria has been met:
Restasis, Restasis Multidose

1. Diagnosis of dry eye disease
2. Trial and failure, or intolerance to artificial tears product
3. Member meets **ONE** of the following:

a. Member will not be using ophthalmic anti-inflammatory drugs concurrently with the requested drug
b. Member meets BOTH of the following:
    i. Member will be using ophthalmic anti-inflammatory drugs concurrently with the requested drug
    ii. The ophthalmic anti-inflammatory drugs will be used concurrently for a short period (2 to 4 weeks) while transitioning to monotherapy with the requested drug

Miebo, Tryptyr, Xiidra

1. Diagnosis of dry eye disease
2. Trial and failure, or intolerance to artificial tears products

Continuation of Therapy

Requests for reauthorization will be approved when all of the following criteria are met:

1. Member demonstrates a positive response to therapy.

Limitations

1. Initial approvals and reauthorizations will be granted for 12 months.

References

1. Miebo (perfluorohexyloctane ophthalmic solution) [prescribing information]. Bridgewater, NJ: Bausch & Lomb Americas Inc.; October 2025.
2. Restasis (cyclosporine) [prescribing information}. North Chicago, IL: Abbvie; September 2024.
3. Roberts CW, et al. Comparison of Topical Cyclosporine, Punctal Occlusion, and a Combination for the Treatment of Dry Eye. Cornea 2007; 26(7):805-809.
4. Tryptyr (acoltremon ophthalmic solution) [prescribing information]. Fort Worth, TX: Alcon Laboratories; May 2025.
5. Xiidra (liftegrast) [prescribing information]. Bridgewater, NJ: Bausch & Lomb Americas Inc.; December 2023.

Review History – Xiidra

11/16/2022 – Reviewed and created for Nov P&T. Switched to custom. Separated out MH vs Comm/Exch. Effective 03/01/2023.
09/09/2026 – Reviewed at September P&T. Retiring policy and adding criteria to new Dry Eye Disease policy. Effective 01/01/2027.

Review History - Restasis

11/16/2022 – Reviewed and created for Nov P&T. Switched to custom. Separated out MH vs Comm/Exch. Effective 03/01/2023.
01/08/2025 – Reviewed and updated for January P&T. Removed documentation requirement from policy. Updated criteria to clarify the NSAID requirements. Effective 04/01/2025.
09/09/2026 – Reviewed at September P&T. Renamed policy “Dry Eye Disease.” Added criteria for Xiidra to this policy, thus retiring Xiidra policy. Adding Miebo and Tryptyr to policy, as agents are being added to the formulary. Effective 01/01/2027.